Pharma BD Deal Intelligence
Xiaflex became a genuine specialty-pharma anchor, but Endo wrote off roughly a fifth of the purchase price within months and the parent company went bankrupt seven years later.
Full analysis, sources & comparables →Leerink's Jason Gerberry highlighted Xiaflex's Peyronie's launch as the key growth catalyst, calling the offered premium a sound exit for Auxilium holders…
Auxilium initially called Endo's $28.10 offer 'significantly undervalued' but signaled willingness to negotiate, foreshadowing the eventual $33.25 close.
Auxilium walked away from its QLT inversion in favor of Endo's $2.6B all-cash-and-stock offer at $33.25/share, a meaningful premium over Endo's initial…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Endo agreed to acquire specialty biopharma Auxilium Pharmaceuticals for $33.25 per share (cash-and-stock) in a deal valued at $2.6B including assumed debt. Auxilium simultaneously terminated its earlier QLT reverse-merger agreement, paying QLT a $28.4M break fee. Closed January 29, 2015.
Xiaflex became a genuine specialty-pharma anchor, but Endo wrote off roughly a fifth of the purchase price within months and the parent company went bankrupt seven years later.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo International plc / Auxilium Pharmaceuticals, Inc. (this deal) | 2014 | $2.6B | 47 |
| Endo International plc / DAVA Pharmaceuticals, Inc. | 2014 | $600M | 25 |
| Endo International plc / Grupo Farmaceutico Somar SAPI de CV | 2014 | $270M | 18 |
| Endo International plc / Par Pharmaceutical Holdings, Inc. | 2015 | $8.1B | 15 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
← Browse all deals · How we score deals
More: 2014 deals · Endo International plc deals · Dermatology deals